XBiotech

05/01/2026

From Lab to Cover: XBiotech Scientists Earn Cover Recognition in the Texas Journal of Microscopy

XBiotech is conducting a Phase I study to evaluate the safety and pharmacokinetics of its stroke therapy candidate, Hutrukin, in healthy volunteers.

03/06/2026

XBiotech Awarded Three U.S. Patents Protecting Next-Generation True Human™ Antibodies Targeting Interleukin-1 Alpha

XBiotech is conducting a Phase I study to evaluate the safety and pharmacokinetics of its stroke therapy candidate, Hutrukin, in healthy volunteers.

02/04/2026

https://www.xbiotech.com/news/advancing-infectious-disease-innovation

XBiotech is conducting a Phase I study to evaluate the safety and pharmacokinetics of its stroke therapy candidate, Hutrukin, in healthy volunteers.

12/23/2024

XBiotech Pauses Rheumatology program
https://investors.xbiotech.com/news-releases/news-release-details/xbiotech-pauses-rheumatology-program

08/23/2024

XBiotech We Believe.

XBiotech’s technologies provide us with the unique ability to develop drug candidates for viral or bacterial infectious diseases. Our core discovery technolo...

06/18/2024

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind,

01/04/2024

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it’s campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation

11/14/2023

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis

(Phase II Multicenter Study is Proceeding Well with High Anticipation) AUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis.

09/26/2023

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I dose escalation clinical

08/21/2023

MILESTONE ACHIEVED IN PHASE I CLINICAL TRIAL FOR HUTRUKIN™ STROKE DRUG

XBiotech

08/08/2023

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis. Natrunix blocks a key cause of inflammation involved